US Oncology

The Woodlands, Texas 77380

1 studies enrolling now · 21 studies all time

What they study most

Advanced Breast Cancer, B Cell Non-Hodgkin's Lymphoma, Breast Cancer, Breast Neoplasm, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chronic Lymphocytic Leukemia, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Fallopian Tube Neoplasms

Studies at this site

• A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer — Recruiting now
• A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Running, not enrolling
• A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer — Running, not enrolling
• Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) — Running, not enrolling
• Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer — Running, not enrolling
• A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC) — Running, not enrolling
• Abemaciclib (LY2835219) Plus Fulvestrant Compared to Placebo Plus Fulvestrant in Previously Treated Breast Cancer — Running, not enrolling
• A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer — Stopped early
• A Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women With Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer — Completed
• A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer — Completed
• A Study of Enzalutamide and LY3023414 in Men With Prostate Cancer — Completed
• Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma — Completed
• Study of Pegilodecakin (LY3500518) With Pembrolizumab Compared to Pembrolizumab Alone First-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• Study of Pegilodecakin (LY3500518) With FOLFOX Compared to FOLFOX Alone Second-line Tx in Participants With Metastatic Pancreatic Cancer — Completed
• Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer — Stopped early
• A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer — Completed
• A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread — Completed
• Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia — Completed
• A Study LY2228820 for Recurrent Ovarian Cancer — Completed
• A Study of Abemaciclib (LY2835219) in Participants With HR+, HER2- Advanced Breast Cancer — Withdrawn before enrolling
• A Study of LY2940680 in Small Cell Lung Cancer — Stopped early